TCF7L2 and nonpapillary renal cell carcinoma: These findings offer opportunities for developing novel drugs targeting TCF7L2 and combination therapies involving lipid-lowering agents and existing targeted treatments, aiming to enhance the treatment results for individuals with advanced and metastatic ccRCC.